Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
10 04 2019
Historique:
pubmed: 28 2 2019
medline: 20 2 2020
entrez: 28 2 2019
Statut: ppublish

Résumé

We evaluated the addition of breast magnetic resonance imaging (MRI) to standard radiologic evaluation on the re-intervention rate in women with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery. Women with biopsy-proven DCIS corresponding to a unifocal microcalcification cluster or a mass less than 30 mm were randomly assigned to undergo MRI or standard evaluation. The primary end point was the re-intervention rate for positive or close margins (< 2 mm) in the 6 months after randomization ( ClinicalTrials.gov identifier: NCT01112254). A total of 360 patients from 10 hospitals in France were included in the study. Of the 352 analyzable patients, 178 were randomly assigned to the MRI arm, and 174 were assigned to the control arm. In the intent-to-treat analysis, 82 of 345 patients with the assessable end point were reoperated for positive or close margins within 6 months, resulting in a re-intervention rate of 20% (35 of 173) in the MRI arm and 27% (47 of 172) in the control arm. The absolute difference of 7% (95% CI, -2% to 16%) corresponded to a relative reduction of 26% (stratified odds ratio, 0.68; 95% CI, 0.41 to 1.1; P = .13). When considering only the per-protocol population with an assessable end point, the difference was 9% (stratified odds ratio, 0.59; 95% CI, 0.35 to 1.0; P = .05). Total mastectomy rates were 18% (31 of 176) in the MRI arm and 17% (30 of 173) in the control arm (stratified P = .93). For 100 lesions seen on MRI, nonmass-like enhancement was more predominant (82%) than mass enhancement (20%). Nevertheless, no specific morphologic and kinetic parameters for DCIS were identified. The study did not show sufficient surgical improvement with the use of preoperative MRI to be clinically relevant in DCIS staging. However, this could be reconsidered with the improvement of new MRI sequences and new modalities in magnetic resonance techniques.

Identifiants

pubmed: 30811290
doi: 10.1200/JCO.18.00595
doi:

Banques de données

ClinicalTrials.gov
['NCT01112254']

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

885-892

Auteurs

Corinne Balleyguier (C)

1 Gustave Roussy, Villejuif, France.
2 Paris-Sud University, Orsay, France.

Ariane Dunant (A)

1 Gustave Roussy, Villejuif, France.

Luc Ceugnart (L)

3 Centre Oscar Lambret, Lille, France.

Marguerite Kandel (M)

1 Gustave Roussy, Villejuif, France.
4 Université Paris-Saclay, Villejuif, France.

Marie-Pierre Chauvet (MP)

3 Centre Oscar Lambret, Lille, France.

Pascal Chérel (P)

5 René Huguenin/Curie, Saint-Cloud, France.

Chafika Mazouni (C)

1 Gustave Roussy, Villejuif, France.

Philippe Henrot (P)

6 Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.

Philippe Rauch (P)

6 Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.

Jocelyne Chopier (J)

7 Tenon Hospital, Paris, France.

Sonia Zilberman (S)

7 Tenon Hospital, Paris, France.

Isabelle Doutriaux-Dumoulin (I)

8 Institut de Cancérologie de l'Ouest, Nantes, France.

Isabelle Jaffre (I)

8 Institut de Cancérologie de l'Ouest, Nantes, France.

Aurélie Jalaguier (A)

9 Institut Paoli Calmettes, Marseille, France.

Gilles Houvenaeghel (G)

9 Institut Paoli Calmettes, Marseille, France.
10 Cancer Research Center of Marseille, Marseille, France.
11 Aix-Marseille Université, Marseille, France.

Nicole Guérin (N)

12 Centre Léon Bérard, Lyon, France.

Françoise Callonnec (F)

13 Centre Henri Becquerel, Rouen, France.

Claire Chapellier (C)

14 Centre Antoine Lacassagne, Nice, France.

Ines Raoust (I)

14 Centre Antoine Lacassagne, Nice, France.

Marie-Christine Mathieu (MC)

1 Gustave Roussy, Villejuif, France.

Françoise Rimareix (F)

1 Gustave Roussy, Villejuif, France.

Julia Bonastre (J)

1 Gustave Roussy, Villejuif, France.
4 Université Paris-Saclay, Villejuif, France.

Jean-Rémi Garbay (JR)

1 Gustave Roussy, Villejuif, France.
† Deceased.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH